Nine companies entered the public market this week, led by customer experience software provider Medallia (MDLA) with a first day pop of 76%. The software company priced at $21, well above the range, to raise $326 million at a fully...read more
Mirum Pharmaceuticals, a late-stage biotech developing therapies for rare cholestatic liver diseases, raised $75 million by offering 5.0 million shares at $15, the midpoint of the $14 to $16 range. Insiders had indicated on purchasing $35 million of the IPO (47%...read more
July's post-holiday flood of IPOs is upon us, with nine diverse offerings and a direct listing scheduled for the second-most active week of the year. The three largest IPOs come from Asia, Europe, and South America, but based on the strong reception of recent...read more
Mirum Pharmaceuticals, a Phase 2 biotech developing therapies for rare liver diseases, announced terms for its IPO on Monday. The Foster City, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the...read more
US IPO Weekly Recap: Medallia tops a 9-IPO week with a 76% first day return
Nine companies entered the public market this week, led by customer experience software provider Medallia (MDLA) with a first day pop of 76%. The software company priced at $21, well above the range, to raise $326 million at a fully...read more
Liver disease biotech Mirum Pharmaceuticals prices IPO at $15 midpoint
Mirum Pharmaceuticals, a late-stage biotech developing therapies for rare cholestatic liver diseases, raised $75 million by offering 5.0 million shares at $15, the midpoint of the $14 to $16 range. Insiders had indicated on purchasing $35 million of the IPO (47%...read more
US IPO Week Ahead: Large foreign filers and a US unicorn lead 10-deal week
July's post-holiday flood of IPOs is upon us, with nine diverse offerings and a direct listing scheduled for the second-most active week of the year. The three largest IPOs come from Asia, Europe, and South America, but based on the strong reception of recent...read more
Liver disease biotech Mirum Pharmaceuticals sets terms for $75 million IPO
Mirum Pharmaceuticals, a Phase 2 biotech developing therapies for rare liver diseases, announced terms for its IPO on Monday. The Foster City, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the...read more